文献速递炎症性肠病消化内镜

利用计算机视觉改善溃疡性结肠炎治疗临床试验中的内镜疾病量化

Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis.
PubMed 文献 · Gastroenterology · 2023-10-11

本研究基于UNIFI试验(乌司奴单抗 vs 安慰剂治疗溃疡性结肠炎)的内镜视频,用计算机视觉将Mayo内镜评分空间映射为累积疾病评分(CDS)。748例诱导期和348例维持期患者中,乌司奴单抗组CDS在第8周和第44周均低于安慰剂组,且CDS较MES更敏感,所需样本量减少50%。

要点

  • CDS与MES及部分Mayo评分临床组分均相关(P < .0001)。
  • 乌司奴单抗组CDS第8周141.9 vs 安慰剂组184.3,第44周78.2 vs 151.5(均P < .0001)。
  • CDS较MES更敏感,展示内镜差异所需样本量减少50%(Hedges' g = 0.743 vs 0.460)。

核心结论

  • CDS作为自动化、定量的全局内镜疾病严重程度指标,为传统MES能力提供人工智能增强,以更好地在临床试验和潜在实践中评估溃疡性结肠炎。

研究设计与样本

  • 研究处理UNIFI临床试验(比较乌司奴单抗与安慰剂治疗中重度活动性溃疡性结肠炎)的内镜视频,用计算机视觉空间映射Mayo内镜评分(MES)生成累积疾病评分(CDS)。
  • 纳入748例诱导期和348例维持期患者,比较CDS与MES区分乌司奴单抗 vs 安慰剂治疗应答及与第44周症状缓解的一致性。
  • 计算CDS和MES检测治疗间内镜差异的统计效能、效应量和估计样本量。
  • 用另一项2期临床试验的复制队列内镜视频验证CDS性能。

主要发现

  • 乌司奴单抗组CDS低于安慰剂组:第8周141.9 vs 184.3(P < .0001),第44周78.2 vs 151.5(P < .0001)。
  • CDS与MES相关(P < .0001),且与部分Mayo评分所有临床组分相关(P < .0001)。
  • 按治疗前CDS分层,乌司奴单抗较安慰剂更有效(P < .0001),且重度 vs 轻度疾病效应增大(-85.0 vs -55.4;P < .0001)。
  • 与MES相比,CDS对变化更敏感,展示乌司奴单抗与安慰剂间内镜差异所需参与者减少50%(Hedges' g = 0.743 vs 0.460)。
  • CDS在JAK-UC复制队列中的性能与UNIFI相似。

关键数值与推荐

  • CDS第8周乌司奴单抗组141.9 vs 安慰剂组184.3(P < .0001)。
  • CDS第44周乌司奴单抗组78.2 vs 安慰剂组151.5(P < .0001)。
  • 按治疗前CDS分层,重度 vs 轻度疾病效应为-85.0 vs -55.4(P < .0001)。
  • CDS所需样本量较MES减少50%(Hedges' g = 0.743 vs 0.460)。

临床怎么用

  • 原文结论指出CDS可人工智能增强传统MES能力,以更好地在临床试验和潜在实践中评估溃疡性结肠炎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Endoscopic assessment of ulcerative colitis (UC) typically reports only the maximum severity observed. Computer vision methods may better quantify mucosal injury detail, which varies among patients. METHODS: Endoscopic video from the UNIFI clinical trial (A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis) comparing ustekinumab and placebo for UC were processed in a computer vision analysis that spatially mapped Mayo Endoscopic Score (MES) to generate the Cumulative Disease Score (CDS). CDS was compared with the MES for differentiating ustekinumab vs placebo treatment response and agreement with symptomatic remission at week 44. Statistical power, effect, and estimated sample sizes for detecting endoscopic differences between treatments were calculated using both CDS and MES measures. Endoscopic video from a separate phase 2 clinical trial replication cohort was performed for validation of CDS performance. RESULTS: Among 748 induction and 348 maintenance patients, CDS was lower in ustekinumab vs placebo users at week 8 (141.9 vs 184.3; P < .0001) and week 44 (78.2 vs 151.5; P < .0001). CDS was correlated with the MES (P < .0001) and all clinical components of the partial Mayo score (P < .0001). Stratification by pretreatment CDS revealed ustekinumab was more effective than placebo (P < .0001) with increasing effect in severe vs mild disease (-85.0 vs -55.4; P < .0001). Compared with the MES, CDS was more sensitive to change, requiring 50% fewer participants to demonstrate endoscopic differences between ustekinumab and placebo (Hedges' g = 0.743 vs 0.460). CDS performance in the JAK-UC replication cohort was similar to UNIFI. CONCLUSIONS: As an automated and quantitative measure of global endoscopic disease severity, the CDS offers artificial intelligence enhancement of traditional MES capability to better evaluate UC in clinical trials and potentially practice.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Stidham RW, Cai L, Cheng S, et al. Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis. Gastroenterology. 2023. PMID: 37832924. doi:10.1053/j.gastro.2023.09.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。